BMYBristol-Myers Squibb Company
# 14 · $61.48 (-2.41%) · $125.59B · Healthcare
Rango 52 semanas
Señales de riesgo alta
El motor de scoring ha marcado estas señales de severidad alta. Son avisos para investigar y no forman parte del score.
- Altman Z in distress zone
Datos de mercado
- P/E
- 13.54
- 1M
- +1.00%
- 1A
- +46.51%
- Rentab.
- 4.10%
- RSI
- 58.16
- MACD
- +0.76%
Desglose
Por qué
- P/E of 13.5
- free cash flow yield 9.1%
- earnings growth of -6.2% a year over 2 years (+178.8% in the latest year alone, inflated by an unusually low prior year)
- ROE of 41.6%
- profit margin of 18.9%
- margin and ROA expanding YoY
- 12-1 momentum return of 45.1%
- trading 4.7% above 200d SMA
- MACD histogram positive
- EPS vs. estimates: +12.8% on average
El razonamiento lo genera el motor de scoring (en inglés).
Piotroski F-Score
8
8 / 9 checks superados
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Señales de riesgo
- Altman Z in distress zoneAlta
Z-Score 1.44 (< 1.81) — financial distress risk per the Altman model
- High leverageMedia
debt/equity 202% (alert threshold 200%)
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Geographic revenue concentrationInfo
69% of revenue from United States
- Product revenue concentrationInfo
97% of revenue from Net Product Sales
Análisis de la empresa
Business Overview Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines in areas including oncology, hematology, immunology, cardiovascular, and neuroscience, generating revenue primarily from branded drug sales to wholesalers, hospitals, and specialty channels. Market Position BMS is a major large-cap pharma competitor with a strong position in oncology and hematology, supported by a broad commercial portfolio and a pipeline spanning multiple therapeutic modalities; competition is driven by clinical differentiation, label breadth, and lifecycle management versus other large innovative biopharmas. Key Segments BMS operates as a single, integrated biopharmaceutical segment, with internal reporting typically organized around therapeutic franchises rather than separately disclosed operating segments.
Resumen generado por IA a partir de datos de terceros; puede contener errores. No constituye asesoramiento financiero ni recomendación de inversión.
Periodo: 2021-12-31 → 2025-12-31